The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Shares in biopharmaceutical group Outlook Therapeutics ($OTLK) collapsed in pre-market trading after the U.S. Food and Drug ...
Biosimilar partnerships and EU approvals surge, enhancing access to innovative treatments in immunology, oncology, and bone ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback